secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001297184-23-000074
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar issues $345M 2% convertible senior notes due 2029; repays $200M term loan, buys $50M stock
--------------------------------------------------------------------------------

- $345M aggregate principal (incl. $45M greenshoe exercised) of 2.00% convertible senior notes due 2029, sold via Rule 144A.
- Initial conversion price ~$62.96 per share, a 35% premium to $46.64 closing price on Sept 12, 2023.
- Net proceeds ~$333.9M; $200M used to repay Wells Fargo credit facility, $50M for stock buyback at $46.64/share.
- Notes convertible under certain conditions; company may redeem on/after Sep 21, 2026 if stock >=130% of conversion price.
- Remaining proceeds earmarked for general corporate purposes, including BAQSIMI milestone payments and potential M&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000074/0001297184-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000074/amph-20230911x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer